DEVA Holding A.Ş. is a leading Turkish pharmaceutical company founded in 1958. As of 2024, it ranked 3rd in unit sales and 6th in TL sales in Turkey’s pharmaceutical market. The company operates three EU GMP- and US FDA-approved facilities in Çerkezköy and Kartepe, with an annual production capacity of 620 million units. DEVA’s portfolio covers 10 therapeutic areas, including cardiovascular, dermatology, ophthalmology, hematology, and anti-infectives, and includes 1,404 registered products across 82 countries. Recognized as Turkey’s top pharmaceutical company in R&D spending by Turkishtime’s 2024 R&D 250 Report, DEVA employs over 500 researchers and 3,000 staff in total. Guided by sustainability and innovation, the company focuses on developing accessible, effective, and environmentally responsible healthcare solutions for both domestic and global markets. Wikipedia